Table 2.
Association of high/low scores for CD3+ TILs and CD68+ TAMs with homologous recombination deficiency.
| HRD status | CD3+ TIL score | CD68+ TAM score | |||||
|---|---|---|---|---|---|---|---|
| Low (0-1) | High (2-3) | P value | Low (0-1) | High (2-3) | P value | Total | |
| non-HRD | 86 (56.6) | 66 (43.4) | 0.001 | 75 (49.3) | 77 (50.7) | 0.015 | 152 |
| HRD | 34 (34.7) | 64 (65.3) | 33 (33.7) | 65 (66.3) | 98 | ||
| BRCA1 mutation | 15 (34.1) | 29 (65.9) | 17 (38.6) | 27 (61.4) | 44 | ||
| BRCA2 mutation | 9 (52.9) | 8 (47.1) | 5 (29.4) | 12 (70.6) | 17 | ||
| Other HRR mutation | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | 13 | ||
| BRCA1/RAD51C hypermethylation | 6 (25.0) | 18 (75.0) | 7 (29.2) | 17 (70.8) | 24 | ||
| Total | 120 (48.0) | 130 (52.0) | 108 (43.2) | 142 (56.8) | 250 | ||
Data shown are n (row %). P value indicates the comparison of non-HRD to HRD ovarian carcinoma. TIL, tumor infiltrating lymphocytes; TAM, tumor-associated macrophages; HRR, homologous recombination-mediate repair, HRD homologous recombination deficient.